Skip to main content

Table 5 Correlation of IMT with demographic, clinical and laboratory characteristics

From: Methotrexate use, not interleukin 33, is associated with lower carotid intima-media thickness in patients with rheumatoid arthritis

Variable   IMT (mm - median (IQR)) P-value
Postmenopausal No 0.60 (0.55–0.65) 0.001a
  Yes 0.71 (0.6–0.8)  
Extra-articular involvement No 0.65 (0.58–0.76) 0.014a
  Yes 0.72 (0.63–0.88)  
SAH Absent 0.60 (0.55–0.71) 0.001a
  Present 0.72 (0.63–0.81)  
Using antihypertensives No 0.62 (0.56–0.71) 0.001a
  Yes 0.73 (0.63–0.81)  
Diabetes mellitus Absent 0.65 (0.58–0.76) 0.003a
  Present 0.84 (0.63–0.95)  
Using hypoglycemic agents/insulin No 0.65 (0.58–0.76) 0.001a
  Yes 0.84 (0.7–1.02)  
LDL within goal No 0.7 (0.6–0.8) 0.012a
  Yes 0.6 (0.6–0.7)  
Metabolic syndrome Absent 0.64 (0.58–0.74) 0.037a
  Present 0.71 (0.6–0.84)  
Using methotrexate No 0.75 (0.62–0.87) 0.005a
  Yes 0.63 (0.58–0.73)  
CVR classificationc High 0.73 (0.61–0.84) < 0.001b
  Intermediate 0.71 (0.64–0.77)  
  Low 0.6 (0.54–0.64)  
IL-33 positived No 0.69 (0.59–0.85) 0.449a
  Yes 0.66 (0.59–0.78)  
  1. aMann-Whitney test; bKruskal-Wallis test
  2. IMT intima-media thickness, IQR interquartile range, SAH systemic arterial hypertension; and CVR cardiovascular risk
  3. caccording to the Global Risk Score (Framingham)
  4. dIL-33 positive: serum IL-33 ≥ 23.4 pg/mL